医療機関、AI向けにパートナーシップを重視
医療提供者の間で、カスタムAIソリューション構築のためにサードパーティベンダーとの提携を求める動きが強まっており、61%の組織が社内開発よりもこのアプローチを選好。米FDAは1,300件を超えるAI搭載医療機器を承認しており、その半数以上が直近3年間のもの。しかし調査データでは、テクノロジーリーダーの77%が未成熟なAIツールを導入の大きな障壁と見なしている。
Health care providers are shifting their AI strategy toward partnerships. A McKinsey study found 61% of health care organizations intend to partner with third-party vendors to develop customized generative AI solutions, favoring collaboration over in-house building or off-the-shelf products. This strategy aims to address specific clinical and operational needs while avoiding implementation failures common in complex health care environments.
Adoption faces significant hurdles despite rising AI utilization. The FDA reports approval of over 1,300 AI-enabled medical devices, with more than 50% authorized in the past three years. However, 77% of surveyed technology leaders cite immature AI tools as a major barrier to adoption. Furthermore, 72% of leaders prioritize reducing caregiver burden, while 53% focus on workflow efficiency, highlighting a demand for administrative tools over purely clinical applications.